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   A 23 year old Caucasian male, with no significant past medial history, was admitted to University Hospital 
for evaluation of fever, chills and back pain.  The patient reported that, five days prior to admission, he devel-
oped intermittent fever and chills with no specific pattern.  He started taking ibuprofen and OTC medications 
for influenza with only partial relief.  Two days prior to admission, he noticed back pain and, on the follow-
ing day, he developed discomfort in his RUQ.  He also reported fatigue and headaches.  The patient denied 
neck stiffness, skin rash, arthralgias, dyspnea, cough, diarrhea, constipation, nausea or vomiting. 
   The patient works on a dairy farm in Missouri, milking, vaccinating and feeding the cattle.  He has had oc-
casional tick bites in the past.  He has smoked half a pack per day for the past five years but denies alcohol 
abuse, illicit drug use or a history of STDs.  He is sexually active with one partner. 
   Nine months prior to his presentation, the patient took a trip to India (Mumbai, Chennai) and Sri Lanka; he 
was traveling for three weeks and visited markets, beaches and an elephant sanctuary.  He reports having 
had multiple mosquito bites during the trip but had taken malaria prophylaxis with doxycycline starting 10 
days prior to the trip and continuing until two weeks after his return; he admits that he may have missed 
some doses.  He ate vegetarian and non-vegetarian food during his vacation.  He denied any symptoms of 
illness while traveling or upon arriving back in the U.S.  After his return, he visited Wyoming, where he 
worked on a cattle breeding ranch and spent a few days in Colorado, where he went rafting and hiking. 
On examination, his temperature was 41.2 C and his other vital signs were stable.  Cardiovascular and lung 
auscultation were unremarkable.  There was some tenderness to palpation of the RUQ and LUQ, his liver 
was palpable 2-3 cm below the right costal margin and splenomegaly was present.  No lympadenopathy, 
edema, urethral discharge, rash or neurologic deficits were found. 
Admission labs revealed WBC 4.2, Hgb 13.2, platelets 41, normal liver enzymes, normal renal function and a 
total bilirubin of 2.5.  A CXR was normal and an ultrasound of the abdomen revealed hepatosplenomegaly.  
G6PD levels were normal.  A peripheral blood smear showed ring forms within RBCs, consistent with Plas-
modium vivax (below):  
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The patient was diagnosed with Plasmodium vivax malaria and was treated with both chloroquine and prima-
quine (the latter to eradicate hypnozoites). 
Discussion: 
   Malaria is a mosquito-borne disease caused by four species of malarial parasites that can infect humans: Plasmo-
dium falciparum, P. vivax, P. ovale and P. malariae.  Patients with malaria often experience fever, chills and a flu-
like illness; if untreated, they may develop severe complications and die.  Each year, 350-500 million cases of ma-
laria occur worldwide, leading to 1 million deaths (most occurring in children in sub-Saharan Africa).  About 1300 
cases of malaria are diagnosed in the U.S. each year; the vast majority of these cases are in travelers or immigrants, 
arriving from sub-Saharan Africa or southern Asia. 
   In most cases, symptoms begin 10 days to 4 weeks after infection, although illness may develop as early as 1 
week and as late as 1 year after inoculation.  Two types of malaria, P. vivax and P. ovale, may have a relapsing 
course; in these infections, some parasites (hypnozoites) remain dormant in the liver for several months (or up to 
four years) after the person is infected.  Once these parasites become active, they invade RBCs and the patient de-
velops acute symptoms (a relapse of the initial illness). 
   In our case, the patient took doxycycline for prophylaxis, an acceptable option when traveling to India and Sri 
Lanka; chloroquine is not indicated for prophylaxis when traveling to those countries.  However, as this case illus-
trates, prophylaxis is not always effective and malarial symptoms may develop up to 1 year after returning from a 
high risk area.  Although there have been rare reports of chloroquine-resistant P. vivax in India, the CDC still rec-
ommends that chloroquine be used as initial treatment, with a switch to a chloroquine-resistant P. vivax regimen if 
clinical response is not documented.  Primaquine is used to eradicate hypnozoites, thereby preventing relapse; 
since primaquine can cause hemolytic anemia in G6PD-deficient persons, G6PD screening is essential prior to 
starting treatment with this drug. 
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